학술논문
Progress in the Typhoid Conjugate Vaccine Program Rollout Supported by Gavi During the COVID-19 Pandemic and the Path Forward.
Document Type
Academic Journal
Author
Russell AL; Vaccine Programs, Gavi, The Vaccine Alliance, Geneva, Switzerland.; Hampton LM; Vaccine Programs, Gavi, The Vaccine Alliance, Geneva, Switzerland.; Sinha A; Vaccine Programs, Gavi, The Vaccine Alliance, Geneva, Switzerland.; Luquero FJ; Vaccine Programs, Gavi, The Vaccine Alliance, Geneva, Switzerland.; Abdelwahab J; Vaccine Programs, Gavi, The Vaccine Alliance, Geneva, Switzerland.
Source
Publisher: Published by Oxford University Press on behalf of the Infectious Diseases Society of America Country of Publication: United States NLM ID: 101637045 Publication Model: eCollection Cited Medium: Print ISSN: 2328-8957 (Print) Linking ISSN: 23288957 NLM ISO Abbreviation: Open Forum Infect Dis Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2328-8957
Abstract
Gavi supports countries to introduce typhoid conjugate vaccine (TCV) with catch-up campaigns. Available TCVs are highly efficacious, equity-focused, and critical to curbing the expansion of antimicrobial resistance. Four Gavi-supported countries have introduced TCVs since 2018. In the wake of the COVID-19 emergency, momentum is building to scale up TCV introduction worldwide, supported by global partners and Gavi's funding for improved typhoid diagnostics.
Competing Interests: Potential conflicts of interest. All authors: no reported conflicts.
(© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Competing Interests: Potential conflicts of interest. All authors: no reported conflicts.
(© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)